ITRM920349A1 - Composizioni farmaceutiche contenenti il-6 - Google Patents

Composizioni farmaceutiche contenenti il-6

Info

Publication number
ITRM920349A1
ITRM920349A1 IT000349A ITRM920349A ITRM920349A1 IT RM920349 A1 ITRM920349 A1 IT RM920349A1 IT 000349 A IT000349 A IT 000349A IT RM920349 A ITRM920349 A IT RM920349A IT RM920349 A1 ITRM920349 A1 IT RM920349A1
Authority
IT
Italy
Prior art keywords
pct
date nov
pharmaceutical compositions
compositions containing
sec
Prior art date
Application number
IT000349A
Other languages
English (en)
Inventor
Filippo Rendina
Fabrizio Samaritani
Original Assignee
Serono Cesare Ist Ricerca
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Cesare Ist Ricerca filed Critical Serono Cesare Ist Ricerca
Publication of ITRM920349A0 publication Critical patent/ITRM920349A0/it
Priority to ITRM920349A priority Critical patent/IT1254359B/it
Priority to EP93909917A priority patent/EP0641216B1/en
Priority to US08/335,874 priority patent/US5635176A/en
Priority to JP51984193A priority patent/JP3714951B2/ja
Priority to DK93909917.2T priority patent/DK0641216T3/da
Priority to AT93909917T priority patent/ATE157256T1/de
Priority to ES93909917T priority patent/ES2105257T3/es
Priority to DE69313444T priority patent/DE69313444T2/de
Priority to PCT/EP1993/001120 priority patent/WO1993023065A1/en
Priority to AU40653/93A priority patent/AU676833B2/en
Priority to CA002117761A priority patent/CA2117761C/en
Publication of ITRM920349A1 publication Critical patent/ITRM920349A1/it
Application granted granted Critical
Publication of IT1254359B publication Critical patent/IT1254359B/it
Priority to GR970402352T priority patent/GR3024708T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ITRM920349A 1992-05-11 1992-05-11 Composizioni farmaceutiche contenenti il-6 IT1254359B (it)

Priority Applications (12)

Application Number Priority Date Filing Date Title
ITRM920349A IT1254359B (it) 1992-05-11 1992-05-11 Composizioni farmaceutiche contenenti il-6
ES93909917T ES2105257T3 (es) 1992-05-11 1993-05-07 Composiciones farmaceuticas que contienen il-6 estabilizadas con un azucar no reductor.
PCT/EP1993/001120 WO1993023065A1 (en) 1992-05-11 1993-05-07 Pharmaceutical compositions containing il-6
JP51984193A JP3714951B2 (ja) 1992-05-11 1993-05-07 Ｉｌ−６含有薬剤組成物
DK93909917.2T DK0641216T3 (da) 1992-05-11 1993-05-07 Farmaceutisk præparat indeholdende IL-6
AT93909917T ATE157256T1 (de) 1992-05-11 1993-05-07 Il-6 enthaltende pharmazeutische zusammensetzungen stabilisiert mit einem nicht- reduzierenden zucker
EP93909917A EP0641216B1 (en) 1992-05-11 1993-05-07 PHARMACEUTICAL COMPOSITIONS CONTAINING IL-6 stabilized with a non-reducing sugar
DE69313444T DE69313444T2 (de) 1992-05-11 1993-05-07 IL-6 ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN stabilisiert mit einem nicht-reduzierenden Zucker
US08/335,874 US5635176A (en) 1992-05-11 1993-05-07 Pharmaceutical compositions containing IL-6
AU40653/93A AU676833B2 (en) 1992-05-11 1993-05-07 Pharmaceutical compositions containing IL-6
CA002117761A CA2117761C (en) 1992-05-11 1993-05-07 Pharmaceutical compositions containing il-6
GR970402352T GR3024708T3 (en) 1992-05-11 1997-09-11 Pharmaceutical compositions containing il-6.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM920349A IT1254359B (it) 1992-05-11 1992-05-11 Composizioni farmaceutiche contenenti il-6

Publications (3)

Publication Number Publication Date
ITRM920349A0 ITRM920349A0 (it) 1992-05-11
ITRM920349A1 true ITRM920349A1 (it) 1993-11-11
IT1254359B IT1254359B (it) 1995-09-14

Family

ID=11400994

Family Applications (1)

Application Number Title Priority Date Filing Date
ITRM920349A IT1254359B (it) 1992-05-11 1992-05-11 Composizioni farmaceutiche contenenti il-6

Country Status (12)

Country Link
US (1) US5635176A (it)
EP (1) EP0641216B1 (it)
JP (1) JP3714951B2 (it)
AT (1) ATE157256T1 (it)
AU (1) AU676833B2 (it)
CA (1) CA2117761C (it)
DE (1) DE69313444T2 (it)
DK (1) DK0641216T3 (it)
ES (1) ES2105257T3 (it)
GR (1) GR3024708T3 (it)
IT (1) IT1254359B (it)
WO (1) WO1993023065A1 (it)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU695129B2 (en) * 1995-02-06 1998-08-06 Genetics Institute, Llc Formulations for IL-12
GB9508691D0 (en) * 1995-04-28 1995-06-14 Pafra Ltd Stable compositions
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
DE19539574A1 (de) 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
US6632648B1 (en) * 1996-05-14 2003-10-14 Elan Drug Delivery Limited Methods of terminal sterilization of fibrinogen
US7141393B2 (en) * 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6433760B1 (en) 1999-01-14 2002-08-13 University Of Central Florida Head mounted display with eyetracking capability
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
EP1356809A4 (en) 2000-12-28 2008-05-14 Takeda Pharmaceutical SUSTAINED RELEASE PREPARATIONS
SI1458360T1 (sl) 2001-12-19 2011-08-31 Novartis Ag Pulmonalno dajanje aminoglikozidov
JP4364645B2 (ja) * 2002-02-14 2009-11-18 中外製薬株式会社 抗体含有溶液製剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457916A (en) * 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
EP0229810B1 (en) * 1985-07-09 1991-10-16 Quadrant Bioresources Limited Protection of proteins and the like
DE3688671T3 (de) * 1985-10-14 2001-05-03 Yeda Res & Dev Menschliches Interferon-beta2A ; Vektoren, die Gene enthalten, die für das genannte Interferon kodieren; Zellinien, die dieses produzieren und Verwendung des genannten Interferons als Pharmazeutikum.
US4762857A (en) * 1986-05-30 1988-08-09 E. I. Du Pont De Nemours And Company Trehalose as stabilizer and tableting excipient
DE3621828A1 (de) * 1986-06-28 1988-01-14 Biotest Pharma Gmbh Stabilisierung eines fuer therapeutische zwecke, insbesondere beim menschen, bestimmten interleukin-2-praeparates sowie dieses praeparat enthaltende stabilisierte waessrige loesung oder feststoff
US5078997A (en) * 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5104651A (en) * 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
JP2805224B2 (ja) * 1989-01-13 1998-09-30 味の素株式会社 血小板減少症治療剤
JPH0327320A (ja) * 1989-06-26 1991-02-05 Ajinomoto Co Inc ヒトｂ細胞分化因子医薬組成物
JPH05963A (ja) * 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US5416071A (en) * 1991-03-12 1995-05-16 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release containing epo and hyaluronic acid
EP0560998A4 (en) * 1991-10-09 1993-12-01 Toray Industries, Inc. Medicine for preventing and treating bleeding tendency
JP3027320U (ja) 1996-01-27 1996-08-09 三千男 高橋 野球グラブの装着補強具

Also Published As

Publication number Publication date
DK0641216T3 (da) 1998-01-26
JPH08502722A (ja) 1996-03-26
EP0641216A1 (en) 1995-03-08
CA2117761A1 (en) 1993-11-25
ITRM920349A0 (it) 1992-05-11
DE69313444T2 (de) 1998-01-02
AU4065393A (en) 1993-12-13
WO1993023065A1 (en) 1993-11-25
JP3714951B2 (ja) 2005-11-09
ES2105257T3 (es) 1997-10-16
ATE157256T1 (de) 1997-09-15
DE69313444D1 (de) 1997-10-02
US5635176A (en) 1997-06-03
GR3024708T3 (en) 1997-12-31
IT1254359B (it) 1995-09-14
AU676833B2 (en) 1997-03-27
CA2117761C (en) 2005-10-04
EP0641216B1 (en) 1997-08-27

Similar Documents

Publication Publication Date Title
MY128629A (en) Stabilized interleukin 2
ITRM920349A1 (it) Composizioni farmaceutiche contenenti il-6
AU590618B2 (en) Stable formulation of biologically active proteins for parenteral injection
ITRM910952A1 (it) Composizioni farmaceutiche contenenti gonadotropine.
NO952321L (no) Polypeptid, samt anti-HIV-preparat fremstilt fra dette
ATE140969T1 (de) Il-3 mit zusätzlichen cysteinresten und chemische modifikationen davon
DK0679092T3 (da) Cytokindæmpende midler
FI910286A0 (fi) Analoger av humant insulin och preparat innehaollande dessa.
AU2634397A (en) A pharmaceutical formulation containing growth hormone, an amino acid and a non-ionic detergent
DK0588539T3 (da) Stabiliserede farmaceutiske præparater indeholdende derivater af vitamin D2 og D3
HU9401831D0 (en) Stabilized pharmaceutical formulations comprising growth hormone and asparagine
DE69420872D1 (de) Hgh enthaltende pharmazeutische zubereitungen
IT1272252B (it) Formulazioni liquide di interferone beta
UA74388C2 (uk) Фармацевтичні композиції тизоксаніду і нітазоксаніду
ATE126063T1 (de) Stabilisierung von therapeutisch wirksamen proteinen in pharmazeutischen zubereitungen.
ATE189262T1 (de) Interferon-alpha/beta bindendes protein, seine herstellung und seine enthaltende pharmazeutische zusammensetzungen
HUP9802286A2 (hu) Stabilizált gyógyszerkészítmény amely valamely növekedési hormont és legalább egy bázikus aminosavmaradékot és legalább egy savas aminosav maradékot tartalmazó peptidet foglal magában
AU7618391A (en) Aqueous pharmaceutical formulations of erythropoietin and the use thereof
JPS6479125A (en) Antitumor agent